GT101 magani ne na ƙwayoyin halitta wanda aka yi da TIL da aka faɗaɗa kuma aka farfaɗo daga ciwon majiyyaci. Ana gudanar da maganin ta hanyar tattara ƙwayoyin ciwon daji daga marasa lafiya da kuma cire TIL. Daga nan za a ƙara girman TIL da aka cire ta amfani da dandamalin masana'anta na Grit Bio na StemTexp® sannan a saka shi cikin marasa lafiya don yaƙar ciwon daji.
A shekarar 2024Taron Shekara-shekara na Ƙungiyar Kula da Cututtukan Cututtuka ta Amurka (ASCO),An bayar da rahoton bayanai kan marasa lafiya 14 masu ciwon daji masu ƙarfi da suka shiga cikin binciken GT101. An tsara gwajin tare da babban ƙarshen ƙarshe kan kimanta DLT da kuma tantance yanayin aminci na GT101 a cikin marasa lafiya da ciwon daji masu ƙarfi da aka auna ta hanyar yawan abubuwan da suka faru na rashin lafiya na Aji ≥ 3 (TEAEs). Maƙallan ƙarshe na biyu sune don tantance sigogin inganci waɗanda suka haɗa da ƙimar amsawa gabaɗaya (ORR), ƙimar sarrafa cututtuka (DCR), rayuwa ba tare da ci gaba ba (PFS), tsawon lokacin amsawa (DOR), da rayuwa gabaɗaya (OS) bisa ga RECIST v1.1.
Sakamako: Ya zuwa ranar 10 ga Nuwamba, 2023, ƙungiyar marasa lafiya 14 sun sami magani tare da matsakaicin shekaru na 46.9 da matsakaicin layuka 2.6 na jiyya da aka yi a baya. Bayan wani magani na yau da kullun na lymphostasis na FC, an yi wa marasa lafiya allurar GT101 a allurai ≥ 5×109 tare da matsakaicin adadin ƙwayoyin 3.7×1010, sannan aka ba da allurar IL-2 mai yawan gaske. Yawancin AEs da aka lura da su na AE ≥ 3 sun shafi tsarin kula da lafiyar FC da IL-2, gami da raguwar adadin lymphocyte, raguwar adadin ƙwayoyin jinin farin jini, raguwar adadin neutrophil, rashin jini, pyrexia da raguwar adadin platelet. Yawancin waɗannan AEs an warke su cikin kwanaki 14, yayin da aka rage wasu kaɗan zuwa ≤ Age 2 cikin makonni 4. Daga cikin marasa lafiya 14 da aka yi wa rajista a cikin alamu daban-daban (kansar huhu ta ƙaramin ƙwayar halitta, melanoma, ciwon daji na mahaifa), ORR ya kasance 35.7%. Musamman ma, maki 4 (28.6%) sun sami wani ɓangare na amsawa (PR), maki 1 (7.1%) sun sami cikakken amsawa (CR), kuma maki 8 (57.1%) suna da rashin lafiya mai ƙarfi (SD) a matsayin mafi kyawun martanin su. maki ɗaya yana da ci gaban cutar da ba a tabbatar ba (PD). Abin lura shi ne, daga cikin marasa lafiya 11/14 da ke fama da cutar kansar mahaifa, ORR ya kasance 45.5% (5/11) tare da maki 4 (36.4%) sun sami PR da maki 1 (9.1%) sun sami CR. An lura da rage cututtuka a cikin maki 10/11 (90.9%), kuma matsakaicin PFS shine watanni 4.2 ga wannan rukunin. Marasa lafiya na CR sun yi bincike na dogon lokaci kuma tsawon lokacin CR da PFS (wanda Kaplan-Meier ya kiyasta) shine makonni 24 da makonni 36, bi da bi. Bayan jiko na GT101, ƙwayoyin T sun faɗaɗa sosai a cikin jinin duk marasa lafiya da ke da matsakaicin Tmax na kwanaki 6.83 kuma matsakaicin kwanaki 15.9.
Kammalawa: A cikin binciken GT101 Phase 1, ba a lura da SAEs da DLT da suka shafi magani ba. A cikin marasa lafiya da ke fama da ciwon daji mai tsanani da aka riga aka yi musu magani kafin a fara magani ko kuma waɗanda suka kamu da cutar, GT101 ya nuna yanayin aminci mai kyau a ƙarƙashin tsarin maganin lymphostasis da IL-2 mai yawan allurai da kuma kyakkyawan yanayin asibiti, musamman a cikin ciwon daji na mahaifa, tare da ORR mai ƙarfafa gwiwa da tsawon lokacin amsawa.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Nassoshi
1.https://www.grit-bio.com/newsinfo/4620292.html
2.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2548
Lokacin Saƙo: Disamba-20-2024